Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 2, 2014

View Archived Issues

Development and characterization of an orally available antifibrotic drug to treat renal fibrosis

Clinical evaluation of the duration between HPIV3 vaccinations in infants

Researchers from Xention present a novel antiarrhythmic therapy candidate

Eli Lilly to begin phase I trial of LY-3009120 in patients with advanced cancer

BioCryst receives funding to advance candidate for Marburg virus disease

Peregrine Pharmaceuticals begins phase III trial of bavituximab

Heat Biologics opens enrollment in phase I/II study of HS-410

Phase I study of AMP-514 begins for advanced solid malignancies

Coagulation factor VIII deficiency as a risk factor for decreased skeletal health

Janssen R&D Ireland discloses new antiviral agents

Pfizer patents novel kynurenine aminotransferase II inhibitors

Lilly patent reports new JAK inhibitors for cancer

New mitochondrial F1F0-ATPase inhibitors designed by Lycera Corp.

Bayer presents preliminary results from a phase II trial of copanlisib in lymphoma

Scientists at Glenmark Pharmaceuticals disclose novel MPGES-1 inhibitors

FDA removes partial clinical hold on Cell Therapeutics' tosedostat

Pfizer files for approval of bosutinib in Japan

RFS Pharma presents novel DAPN phosphoramidate prodrugs with promising activity against HCV

NICE publishes final draft guidance recommending aflibercept for macular edema

NICE final draft guidance recommends funding of pixantrone

NICE issues new draft guidance recommending Firmagon for prostate cancer

PanOptica to study PAN-90806 in patients with wet AMD

NINDS investigates SGS-742 in phase II trial for SSADH deficiency

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...